Briefly noted: A recent study (EA Spencer et al.Inflamm Bowel Dis 2018; 24: 1335-42) examined phenotype and serology in 399 children with newly diagnosed ulcerative colitis (PROTECT study).
Key findings:
- 65% had positive serology for pANCA; 62% in those <12 and 66% in those ≥12 years
- 19% had positive serology for anti-CBir1; 32% in those <12 and 14% in those ≥12 years
- High titer (≥ 100)) pANCA positivity was associated with more extensive disease but not with PUCAI values or Mayo endoscopic subscores.
My take: The serology titers for IBD, in my view, have academic interest but do not routinely enhance patient care.
Related blog post:
- Low-Value Care: IBD Serologies for Diagnosis of IBD
- How helpful are serologies in pediatric inflammatory bowel disease?
